Clinical progression in Parkinson disease and the neurobiology of axons

Cited by (1,001)

Items 501–600 of 1,001

1. Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson’s disease: a Complete Review
   Sidharth Mehan, Gurkirat Kaur, Rajesh Dudi, M Rajput, Sanjeev Kalra · 2017 · Open Journal of Parkinson s Disease and Treatment
2. Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice
   Shinya Okuda, Norihito Uemura, Masanori Sawamura, Tomoyuki Taguchi, Masashi Ikuno, Maiko T. Uemura, Hodaka Yamakado, Ryōsuke Takahashi · 2021 · Neurotherapeutics
3. Diet Quality is Associated with Prodromal Parkinson's Disease Features in Chinese Adults
   Xinyuan Zhang, Jipo Xu, Yesong Liu, Shuohua Chen, Shouling Wu, Xiang Gao · 2022 · Movement Disorders
4. Axonal degeneration in the anterior insular cortex is associated with Alzheimer’s co-pathology in Parkinson’s disease and dementia with Lewy bodies
   Yasmine Y. Fathy, Laura E. Jonkman, John G. J. M. Bol, Evelien Timmermans, Allert J. Jonker, Annemieke J.M. Rozemüller, Wilma D. J. van de Berg · 2022 · Translational Neurodegeneration
5. PDDS: A software for the early diagnosis of Parkinson’s disease from MRI and DaT scan images using detection and segmentation algorithms
   Tewodros Megabiaw Tassew, Xuan Nie, Bosong Chai · 2023 · Biomedical Signal Processing and Control
6. Gene Expression Profiling of Post Mortem Midbrain of Parkinson’s Disease Patients and Healthy Controls
   Michele Salemi, Maria Ravo, Giuseppe Lanza, Francesca A. Schillaci, Giovanna Maria Ventola, Giovanna Marchese, Maria Grazia Salluzzo, Graziella Cappelletti, Raffaele Ferri · 2024 · International Journal of Molecular Sciences
7. PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
   Frida Lind‐Holm Mogensen, Carole Sousa, Corrado Ameli, Katja Badanjak, Sandro L. Pereira, Arnaud Muller, Tony Kaoma, Djalil Coowar, Andrea Scafidi, Suresh Kumar Poovathingal et al. · 2024 · Journal of Neuroinflammation
8. The role of α-synuclein in neurodegeneration — An update
   K. A. Jellinger · 2012 · Translational Neuroscience
9. Regional susceptibilities to mitochondrial dysfunctions in the CNS
   Milena Pinto, Alicia M. Pickrell, Carlos Torres Moraes · 2012 · Biological Chemistry
10. Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism
    Pollyana Caldeira Leal, José M.M. Bispo, Lívia C.R.F. Lins, Marina F. Souza, Auderlan Mendonça de Gois, Cindy Moore, Murilo Marchioro, Alessandra Mussi Ribeiro, Regina H. Silva, Charles K. Meshul et al. · 2019 · Brain Research Bulletin
11. Layer-specific axonal degeneration of serotonergic fibers in the prefrontal cortex of aged A53T α-synuclein–expressing mice
    Jeanette Wihan, Janina Grosch, Liubov S. Kalinichenko, Christian P. Müller, Jürgen Winkler, Zacharias Kohl · 2019 · Neurobiology of Aging
12. Neuroprotective and reparative effects of endoplasmic reticulum luminal proteins – mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factor
    Katrina Albert, Mikko Airavaara · 2019 · Croatian Medical Journal
13. The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade?
    Natalia Salvadores, Felipe A. Court · 2020 · Expert Opinion on Therapeutic Targets
14. PDLens
    Hanbin Zhang, Gabriel Guo, Chen Song, Chenhan Xu, Kevin Yiu-Wah Cheung, Jasleen Alexis, Huining Li, Dongmei Li, Kun Wang, Wenyao Xu · 2020 · ACM Annual International Conference on Mobile Computing and Networking (MobiCom)
15. Olive Oil Polyphenols in Neurodegenerative Pathologies
    Constantinos Salis, Louis Papageorgiou, Eleni Papakonstantinou, Marianna Hagidimitriou, Dimitriοs Vlachakis · 2020 · Advances in experimental medicine and biology
16. Alterations of Sleep and Sleep Oscillations in the Hemiparkinsonian Rat
    Jelena Ciric, Slobodan Kapor, Milka Perović, Jasna Šaponjić · 2019 · Frontiers in Neuroscience
17. Assessing the Limitations and Biases in the Current Understanding of Chronic Traumatic Encephalopathy
    Schwab, Nicole, Hazrati, Lili-Naz · 2018 · Journal of Alzheimer’s Disease
18. Impaired Glymphatic Clearance, Measured Using Diffusion Tensor Image Analysis Along the Perivascular Space ( DTI ‐ ALPS) , is Linked to Poor Cognitive Outcomes in Parkinson's Disease
    Angeliki Zarkali, George E. C. Thomas, Ross W. Paterson, Naomi Hannaway, Ivelina Dobreva, Amanda Heslegrave, Elena Veleva, Henrik Zetterberg, Rimona Sharon Weil · 2025 · Movement Disorders
19. Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): Implications for cognitive deficits in a progressive animal model for Parkinson’s disease
    Anderson H.F.F. Leão, Ywlliane da Silva Rodrigues Meurer, Thalma Ariani Freitas, André M. Medeiros, Vanessa Costhek Abílio, Geison Souza Izídio, Isaltino Marcelo Conceição, Alessandra Mussi Ribeiro, Regina H. Silva · 2021 · Behavioural Brain Research
20. Dopamine Neuron Challenge Test for early detection of Parkinson’s disease
    Jingheng Zhou, Ji‐Cheng Li, Amy B. Papaneri, Nicholas P. Kobzar, Guohong Cui · 2021 · npj Parkinson s Disease
21. Inhibition of Wnt/β-catenin signaling attenuates axonal degeneration in models of Parkinson's disease
    Yan-Lin Huang, Jian-Nan Zhang, Tian‐Zhong Hou, Li Gu, Hui-Min Yang, Hong Zhang · 2022 · Neurochemistry International
22. A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson’s Disease
    Chelsea O’Day, David Isaac Finkelstein, Shanti Diwakarla, Rachel Mai McQuade · 2022 · Journal of Parkinson s Disease
23. Microfluidic Biosensor Decorated with an Indium Phosphate Nanointerface for Attomolar Dopamine Detection
    Ying Li, Chiao-Chun Chang, Chu Wang, Wen‐Ti Wu, Chih‐Min Wang, Hsiung‐Lin Tu · 2023 · ACS Sensors
24. Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank
    Yuanfeng Huang, Qian Chen, Zheng Wang, Yijing Wang, Aojie Lian, Qiao Zhou, Guihu Zhao, Kun Xia, Beisha Tang, Bin Li et al. · 2024 · npj Parkinson s Disease
25. Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils
    Joseph R. Patterson, Joseph J. Kochmanski, Anna C. Stoll, Michael Kubik, Christopher J. Kemp, Megan F. Duffy, Kaje’ne E. Thompson, Jacob W. Howe, Allyson Cole-Strauss, Nathan C. Kuhn et al. · 2024 · npj Parkinson s Disease
26. Optogenetic and chemogenetic approaches for modeling neurological disorders in vivo
    Viktoriya G. Krut’, Andrei L. Kalinichenko, Dmitry I. Maltsev, David Jappy, Evgeny K. Shevchenko, Oleg V. Podgorny, Vsevolod Vadimovich Belousov · 2024 · Progress in Neurobiology
27. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease
    Johannes C. M. Schlachetzki, Franz Marxreiter, Martin Regensburger, Anna O. Kulinich, Beate Winner, Jürgen Winkler · 2014 · Restorative Neurology and Neuroscience
28. Comparative study between bone marrow mesenchymal stem cell and their conditioned medium in the treatment of rat model of Parkinsonism
    Soha Abdelkawy Abdelwahab, Sara Abdel Gawad Elsebay, Manar Fouli Gaber Ibrahim, Sara Mohamed Naguib Abdel Hafez · 2020 · Journal of Cellular Physiology
29. Simplified quantification of [ 18 F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium
    Joachim Brumberg, Vera S. Kerstens, Zsolt Cselényi, Per Svenningsson, Mathias Sundgren, Patrik Fazio, Andrea Varrone · 2020 · Journal of Cerebral Blood Flow & Metabolism
30. Efeitos da estimulação cerebral profunda bilateral do núcleo subtalâmico sobre a sensibilidade e a dor em indivíduos com doença de Parkinson idiopática
    Rubens Gisbert Cury · 2015 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
31. Emerging roles of leptin in Parkinson’s disease: Chronic inflammation, neuroprotection and more?
    Regensburger, Martin, Rasul Chaudhry, Shafqat, Yasin, Hammad, Zhao, Yining, Stadlbauer, Andreas, Buchfelder, Michael, Kinfe, Thomas · 2023 · Brain, Behavior, and Immunity
32. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson’s disease
    Peter Owen Jenkins, Andreas–Antonios Roussakis, Sara De Simoni, Niall Bourke, Jessica Fleminger, James Howard Cole, Paola P. Piccini, David James Sharp · 2020 · Journal of Neurology Neurosurgery & Psychiatry
33. Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease
    Aaron W. Beger, Beatrix Dudzik, Randall L. Woltjer, Paul L. Wood · 2022 · Metabolites
34. Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms
    Lara Petricca, Nour Chiki, Layane Hanna-El-Daher, Lorène Aeschbach, Ritwik Burai, Erik Stoops, Mohamed-Bilal Fares, Hilal Ahmed Lashuel · 2022 · Journal of Parkinson s Disease
35. Haploinsufficiency of ITSN1 is associated with a substantial increased risk of Parkinson’s disease
    Thomas P Spargo, Chloe F. Sands, Isabella R. Juan, Jonathan Mitchell, Vida Ravanmehr, Jessica C. Butts, Ruth B. De-Paula, Youngdoo Kim, Fengyuan Hu, Quanli Wang et al. · 2025 · Cell Reports
36. Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line
    Mathieu Schmitt, Benjamin Dehay, Erwan Bézard, F. Javier Garcia-Ladona · 2015 · Synapse
37. What to Test in Parkinson Disease Prevention Trials?
    Grace F. Crotty, Michael A. Schwarzschild · 2022 · Neurology
38. Anti-Neuroinflammatory, Protective Effects of the Synthetic Microneurotrophin BNN-20 in the Advanced Dopaminergic Neurodegeneration of “Weaver” Mice
    Panagiotakopoulou, Vasiliki, Botsakis, Konstantinos, Delis, Foteini, Mourtzi, Theodora, Tzatzarakis, Manolis N., Dimopoulou, Aggeliki, Poulia, Nafsika, Antoniou, Katerina, Stathopoulos, Georgios T., Matsokis, Nikolaos et al. · 2020 · Neuropharmacology
39. Sleep Disorders in Neurodegenerative Diseases with Dementia: A Comprehensive Review
    Natalia Siwecka, Michał Golberg, Dominika Świerczewska, Beata Filipek, Karolina Pendrasik, Adrianna Bączek-Grzegorzewska, Mariusz Stasiołek, Mariola Matysiak · 2025 · Journal of Clinical Medicine
40. Ndufs4 ablation decreases synaptophysin expression in hippocampus
    Subrata Kumar Shil, Yoshiteru Kagawa, Banlanjo Abdulaziz Umaru, Fumika Nanto-Hara, Hirofumi Miyazaki, Yui Yamamoto, Shuhei Kobayashi, Chitose Suzuki, Takaaki Abe, Yuji Owada · 2021 · Scientific Reports
41. p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1
    So-Yoon Won, Jungjin Park, Soon-Tae You, Jong-A Hyeun, Hyong Kyu Kim, Byung Kwan Jin, Catriona McLean, Eun‐Young Shin, Eung‐Gook Kim · 2022 · Cell Death and Disease
42. BERT Learns From Electroencephalograms About Parkinson’s Disease: Transformer-Based Models for Aid Diagnosis
    Alberto Nogales, Álvaro José García-Tejedor, Ana María Maitín, Antonio Perez-Morales, M. Dolores del Castillo, Juan Pablo Romero · 2022 · IEEE Access
43. In vivo overexpression of synaptogyrin‐3 promotes striatal synaptic dopamine uptake in LRRK2 R1441G mutant mouse model of Parkinson's disease
    Philip Wing‐Lok Ho, Lingfei Li, Hui‐Fang Liu, Zoe Yuen-Kiu Choi, Eunice Eun Seo Chang, Shirley Yin‐Yu Pang, Yasine Malki, Chi-Ting Leung, Michelle Hiu-Wai Kung, David Boyer Ramsden et al. · 2023 · Brain and Behavior
44. Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects
    Helen M Collins, Susan Adele Greenfield · 2024 · International Journal of Molecular Sciences
45. Preclinical signs of Parkinson's disease: A possible association of Parkinson's disease with skin and hair features
    Neringa Jucevičiūtė, Indrė Banaitytė - Baleišienė, Antanas Vaitkus, Renata Balnytė · 2019 · Medical Hypotheses
46. Classification of Patients with Parkinson’s Disease Using Medical Imaging and Artificial Intelligence Algorithms
    Helena Rico Pereira, Hugo Alexandre Ferreira · 2019 · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany
47. Immune-associated biomarkers for early diagnosis of Parkinson’s disease based on hematological lncRNA–mRNA co-expression
    Kecheng Lei, Liwen Zhang, Yijing He, Hui Sun, Weifang Tong, Yichun Xu, Lingjing Jin · 2020 · Bioscience Reports
48. Mental Disturbances in Parkinson's Disease and Related Disorders: The Role of Excitotoxins
    Izabella Obál, Zsófia Majláth, József Toldi, László Vécsei · 2014 · Journal of Parkinson s Disease
49. An autophagic mechanism is involved in the 6-hydroxydopamine-induced neurotoxicity in vivo
    Xin He, Wei Yuan, Zijian Li, Juan Feng · 2017 · Toxicology Letters
50. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease: mechanisms, biomarkers, and therapeutic strategies
    Pothu Ushakiran, Jigar Haria, Reena Rani, Sudhir Kumar Singh · 2025 · Tissue Barriers
51. Parkinson's disease – pathology, aetiology and diagnosis
    Graeme J.A. Macphee, David Alan Stewart · 2012 · Reviews in Clinical Gerontology
52. α-synucleinopathy exerts sex-dimorphic effects on the multipurpose DNA repair/redox protein APE1 in mice and humans
    Kristin M. Miner, Anuj S. Jamenis, Tarun N. Bhatia, Rachel N. Clark, Dhivyaa Rajasundaram, Sylvie Sauvaigo, Daniel M. Mason, Jessica M. Posimo, Nevil Abraham, Brett A. DeMarco et al. · 2022 · Progress in Neurobiology
53. Cortical Lewy body injections induce long-distance pathogenic alterations in the non-human primate brain
    Margaux Teil, Sandra Doveró, Mathieu Bourdenx, Marie-Laure Arotçarena, Morgane Darricau, Grégory Porras, Marie-Laure Thiolat, Inés Trigo‐Damas, Céline Perier, Cristina M. Estrada et al. · 2023 · npj Parkinson s Disease
54. Metabolic Basis of Circadian Dysfunction in Parkinson’s Disease
    Priya Rathor, Ratnasekhar Ch · 2023 · Biology
55. Opicapone to Treat Early Wearing‐off in Parkinson's Disease Patients: The Korean ADOPTION Trial
    Jee‐Young Lee, Hyeo‐Il Ma, Joaquim José Ferreira, José‐Francisco Rocha, Young Hee Sung, In‐Uk Song, Tae‐Beom Ahn, Do-Young Kwon, Sang‐Myung Cheon, Jong‐Min Kim et al. · 2024 · Movement Disorders Clinical Practice
56. In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration
    Jeanette M. Metzger, Colleen F. Moore, Carissa Boettcher, Kevin G. Brunner, Rachel A. Fleddermann, Helen N. Matsoff, Henry Resnikoff, Viktoriya Bondarenko, Timothy J. Kamp, Timothy A. Hacker et al. · 2018 · npj Parkinson s Disease
57. Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model
    William B. Lynch, Christopher W. Tschumi, Amanda Lea Sharpe, Sarah Y. Branch, Cang Chen, Guo Ge, Senlin Li, Michael J. Beckstead · 2018 · Movement Disorders
58. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease
    Jian-Nan Zhang, Yan-Lin Huang, Hui-Min Yang, Yuan Wang, Li Gu, Hong Zhang · 2020 · Molecular and Cellular Neuroscience
59. A geroscience approach for Parkinson’s disease: Conceptual framework and design of PROPAG-AGEING project
    Chiara Pirazzini, Tiago Azevedo, Luca Baldelli, Anna Bartoletti‐Stella, Giovanna Calandra Buonaura, Alessandra Dal Molin, Giovanna Maria Dimitri, Ivan Doykov, Pilar Gómez‐Garre, Sara Hägg et al. · 2020 · Mechanisms of Ageing and Development
60. Early functional changes associated with alpha-synuclein proteinopathy in engineered human neural networks
    Vibeke Devold Valderhaug, Kristine Heiney, Ola Huse Ramstad, Geir Bråthen, Wei‐Li Kuan, Stefano Nichele, Axel Sandvig, Ioanna Sandvig · 2021 · American Journal of Physiology-Cell Physiology
61. Plasma proteome profiling using tandem mass tag labeling technology reveals potential biomarkers for Parkinson's disease: a preliminary study
    Yuan Zhao, Yidan Zhang, Jian Zhang, Guofeng Yang · 2021 · PROTEOMICS - CLINICAL APPLICATIONS
62. Comparison of vagus nerve cross-sectional area between brain-first and body-first Parkinson’s disease
    Shuangshuang Dong, Bo Shen, Xu Jiang, Jun Zhu, Hai‐Ying Zhang, Yang Zhao, Yaning Chen, Dongfeng Li, Yuanyuan Feng, Yi Chen et al. · 2024 · npj Parkinson s Disease
63. Effects of Gut Microbiota Alterations on Motor, Gastrointestinal, and Behavioral Phenotype in a Mouse Model of Parkinson’s Disease
    Nina Radisavljevic, Mihai S. Cirstea, Kylynda C. Bauer, Christine Lo, Avril Metcalfe‐Roach, Tahereh Bozorgmehr, Haggai Bar‐Yoseph, B. Brett Finlay · 2022 · Journal of Parkinson s Disease
64. Subregional analysis of striatum iron in Parkinson’s disease and rapid eye movement sleep behaviour disorder
    Erind Alushaj, Dimuthu Hemachandra, Alan B Kuurstra, Ravi S. Menon, Hooman Ganjavi, Manas Sharma, Alia Kashgari, Jennifer Barr, William Michael Reisman, ALI RAZA KHAN et al. · 2023 · NeuroImage Clinical
65. Velusetrag rescues GI dysfunction, gut inflammation and dysbiosis in a mouse model of Parkinson’s disease
    Jéssica Grigoletto, Fabiana Miraglia, Laura Benvenuti, Carolina Pellegrini, Sara Soldi, Serena Galletti, Antonino Cattaneo, Emilio Merlo Pich, Maria Grimaldi, Emanuela Colla et al. · 2023 · npj Parkinson s Disease
66. Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidence
    Zeying Feng, Qiuping Zhao, Jingjing Wu, Yiping Yang, Xinru Jia, Junlong Ma, Haibo Tang, Hong Yuan, Guoping Yang, Yao Lu · 2023 · BMC Medicine
67. Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform
    Martin Schuler, Grischa Gerwert, Marvin Mann, Nathalie Woitzik, Lennart Langenhoff, Diana Hubert, Deniz Duman, Adrian Höveler, Sandy Galkowski, Jonas Simon et al. · 2025 · EMBO Molecular Medicine
68. Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease
    José Vicente Lafuente, Catalina Requejo, Alejandro Carrasco, Harkaitz Bengoetxea · 2017 · International review of neurobiology
69. Conditioning Against the Pathology of Parkinson's disease.
    Rehana K. Leak · 2018 · PubMed
70. Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson’s disease
    Xiaodan Liu, Qilong Wang, Ying Yang, Tessandra Stewart, Min Yan Shi, David Soltys, Genliang Liu, Eric Thorland, Eugene M. Cilento, Yiran Hou et al. · 2021 · Acta Neuropathologica Communications
71. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson’s disease
    Thomas Musacchio, Jing Yin, Fabian Kremer, James B. Koprich, Jonathan M. Brotchie, Jens Volkmann, Chi Wang Ip · 2022 · Behavioural Brain Research
72. Tract-Based Spatial Statistics Reveal Lower White Matter Integrity Specific to Idiopathic Rapid Eye Movement Sleep Behavior Disorder as a Proxy for Prodromal Parkinson’s Disease
    Lisa Ohlhauser, Colette M. Smart, Jodie R. Gawryluk · 2019 · Journal of Parkinson s Disease
73. Tau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study
    Allan K. Hansen, Peter Parbo, Rola Ismail, Karen Østergaard, David James Brooks, Per Borghammer · 2019 · Journal of Parkinson s Disease
74. Parkinson's Disease
    K. A. Jellinger · 2011 · Wiley eBooks
75. Visual and Cognitive Impairments Differentially Affect Speed Limit Compliance in Older Drivers
    Shefang Wang, Anuj Sharma, Jeffrey D. Dawson, Matthew Rizzo, Jennifer Merickel · 2021 · Journal of the American Geriatrics Society
76. Motor Dysfunction in REM Sleep Behavior Disorder: A Rehabilitation Framework for Prodromal Synucleinopathy
    Rebekah L. S. Summers, Miriam R. Rafferty, Michael J. Howell, Colum D. MacKinnon · 2021 · Neurorehabilitation and neural repair
77. Fast and robust supervised machine learning approach for classification and prediction of Parkinson’s disease onset
    Lavanya Madhuri Bollipo, K. V. Kadambari · 2021 · Computer Methods in Biomechanics and Biomedical Engineering Imaging & Visualization
78. Aberrant Synaptic Pruning in CNS Diseases: A Critical Player in HIV-Associated Neurological Dysfunction?
    Zachary Watson, Shao‐Jun Tang · 2022 · Cells
79. The effect of age and disease duration on the efficacy of subthalamic nuclei deep brain stimulation in Parkinson's disease patients
    Tingting Du, Tianshuo Yuan, Guanyu Zhu, Ruoyu Ma, Xin Zhang, Ying‐Chuan Chen, Jianguo Zhang · 2022 · CNS Neuroscience & Therapeutics
80. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
    Praveen Honhar, Faranak Ebrahimian Sadabad, Sule Tinaz, Jean‐Dominique Gallezot, Mark Dias, Mika Naganawa, Yanghong Yang, Shannan E. Henry, Ansel T. Hillmer, Hong Gao et al. · 2024 · Brain Communications
81. Nanodelivery of therapeutic agents in Parkinson's disease
    José Vicente Lafuente, Catalina Requejo, Luisa Ugedo · 2019 · Progress in brain research
82. Pharmacological management of Parkinson’s disease in older people
    Nadia Mouchaileh, Andrew Jerome Hughes · 2020 · Journal of Pharmacy Practice and Research
83. Tocotrienols protect differentiated SH-SY5Y human neuroblastoma cells against 6-hydroxydopamine-induced cytotoxicity by ameliorating dopamine biosynthesis and dopamine receptor D2 gene expression
    Kasthuri Bai Magalingam, Sushela Devi Somanath, Shadab Md, Nagaraja Haleagrahara, Ju‐Yen Fu, Kanga Rani Selvaduray, Ammu Kutty Radhakrishnan · 2021 · Nutrition Research
84. Exercise-Boosted Mitochondrial Remodeling in Parkinson’s Disease
    Juan Carlos Magaña, Cláudia M. Deus, Maria Giné‐Garriga, Joel Montané, Susana P. Pereira · 2022 · Biomedicines
85. Sex, dopamine, and hypokinesia: A study of inflectional morphology in Parkinson’s disease.
    Karim Johari, Matthew Walenski, Jana Reifegerste, Farzad Ashrafi, Michael T. Ullman · 2019 · Neuropsychology
86. Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors
    Yuan‐Hao Chen, Tsung-Hsun Hsieh, Tung‐Tai Kuo, Jen‐Hsin Kao, Kuo‐Hsing Ma, Eagle Yi‐Kung Huang, Yu‐Ching Chou, Lars Olson, Barry J. Hoffer · 2019 · Journal of Neurochemistry
87. Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration
    Jeanette M. Metzger, Helen N. Matsoff, Alexandra D. Zinnen, Rachel A. Fleddermann, Viktoriya Bondarenko, Heather A. Simmons, Andres F. Mejia, Colleen F. Moore, Marina Elena Emborg · 2020 · PLoS ONE
88. Africanized Bee Venom (Apis mellifera Linnaeus): Neuroprotective Effects in a Parkinson’s Disease Mouse Model Induced by 6-hydroxydopamine
    Camila Gomes Dantas, Ailma Oliveira da Paixão, Tássia Luiza Gonçalves Magalhães Nunes, Italo J. F. Silva, Bruno dos S. Lima, Adriano Antunes de Souza Araújo, Ricardo Luiz Cavalcanti de Albuquerque Júnior, Kátia Peres Gramacho, Francine Ferreira Padilha, Luiz Pereira da Costa et al. · 2022 · Toxics
89. Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?
    Giovanni Palermo, Alessandro Galgani, Gabriele Bellini, Francesco Paolo Lombardo, Nicola Martini, Riccardo Morganti, Davide Paoli, Sara De Cori, Francesca Frijia, Gabriele Siciliano et al. · 2023 · Journal of Neural Transmission
90. Silencing Parkinson’s risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability
    Patrick J. Kearney, Yuanxi Zhang, Marianna Liang, Yanglan Tan, Elizabeth W. Kahuno, Tucker L. Conklin, Rita R. Fagan, Rebecca G. Pavchinskiy, Scott A. Shaffer, Zhenyu Yue et al. · 2024 · npj Parkinson s Disease
91. Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson’s disease phenotypes
    Silke Nuber, Xiaoqun Zhang, Thomas D. McCaffery, Tim E. Moors, Marie-Alexandre Adom, Wolf N. Hahn, Dylan Martin, Maria Ericsson, Arati Tripathi, Ulf Dettmer et al. · 2024 · npj Parkinson s Disease
92. Non-motor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson’s disease
    Anna Radlicka-Borysewska, Judyta Jabłońska, Michał Lenarczyk, Łukasz Szumiec, Zofia Harda, Monika Bagińska, Justyna Barut, Joanna Pera, Grzegorz Kreiner, Daniel Krzysztof Wojcik et al. · 2024 · Frontiers in Neuroscience
93. Update on the Role of [18F]FDOPA PET/CT
    Gilles N. Stormezand, Eline de Meyer, Klaas Pieter Koopmans, Adrienne H. Brouwers, Gert Luurtsema, Rudi A. J. O. Dierckx · 2024 · Seminars in Nuclear Medicine
94. 810-nm Photobiomodulation Evokes Glutamate Release in Normal and Rotenone-Dysfunctional Cortical Nerve Terminals by Modulating Mitochondrial Energy Metabolism
    Silvia Ravera, Elisa Farsetti, Guido Maura, Manuela Marcoli, Matteo Bozzo, Chiara Cervetto, Andrea Amaroli · 2025 · Cells
95. Peripheral immune cell response to stimulation stratifies Parkinson’s disease progression from prodromal to clinical stages
    Julian R Mark, Ann M. Titus, Hannah A. Staley, Stephan D. Alvarez, Savanna Mahn, Nikolaus R. McFarland, Rebecca L. Wallings, Malú G. Tansey · 2025 · Communications Biology
96. The Role of MicroRNA in the Pathogenesis and Diagnostics of Parkinson’s Disease
    Natalia S. Ardashirova, E. Yu. Fedotova, Sergey Nikolaevich Illarioshkin · 2020 · Neurochemical Journal
97. Too much for your own good: Excessive dopamine damages neurons and contributes to Parkinson's disease
    Anna Masato, Luigi Bubacco, Elisa Greggio · 2021 · Journal of Neurochemistry
98. Presymptomatic MPTP Mice Show Neurotrophic S100B/ mRAGE Striatal Levels
    Sofia Viana, Rosa Fernandes, Paula M. Canas, Andréa M. Silva, Félix Dias Carvalho, Syed F. Ali, Carlos Ribeiro, Frederico Costa Pereira · 2016 · CNS Neuroscience & Therapeutics
99. Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease
    Chiara Milanese, Sylvia Gabriels, Sander Barnhoorn, Silvia Cerri, Ayşe Ulusoy, Simona V. Gornati, Daniel F. Wallace, Fabio Blandini, Donato A. Di Monte, V. Nathan Subramaniam et al. · 2020 · Cell Death and Differentiation
100. The Determination of Trimethylamine N-Oxide and Organic Acids Connected with Gut Microbiota in the Urine of Parkinson’s Disease Patients: A Pilot Study
     Paulina Gątarek, Małgorzata Pawelczyk, Barbara Bobrowska‐Korczak, Joanna Giebułtowicz, Andrzej R Glabinski, Joanna Kałużna‐Czaplińska · 2025 · International Journal of Molecular Sciences